EirGenix (6589) Fundamentals 2026 — Revenue Analysis | SniperIQ
EirGenix (6589) is a TW-listed Healthcare company in Biotechnology with a market capitalization of NT
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is EirGenix's market cap?
EirGenix (6589) has a market capitalization of approximately NT
What is EirGenix's P/E ratio?
EirGenix's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is EirGenix?
EirGenix runs a net profit margin of -65.9%, a gross margin of 18.5%, and an operating margin of -72.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does EirGenix generate?
EirGenix reported revenue of NT
Does EirGenix pay a dividend?
EirGenix does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is EirGenix financially healthy?
EirGenix carries a debt-to-equity ratio of 0.19x and a current ratio of 4.60x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is EirGenix a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For EirGenix (6589) the key facts are: market cap NT
Track EirGenix's full fundamentals live
Get EirGenix's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.